Inventor · disambiguated record
Anthony P. Ford
Also filed as: FORD ANTHONY P · FORD ANTHONY P D W
24 granted patents·24 pending applications·89 citations·filing 2000–2024
95Inventor score
Files withCURASEN THERAPEUTICS INC18AFFERENT PHARMACEUTICALS INC16ROCHE PALO ALTO LLC7SYNTEX LLC3BROKA CHRIS ALLEN1
Top patents by PatentIndex Score
48 records- 0193US8008313B2Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2006·Granted Aug 30, 2011·20 cites·13 claims
- 0291US11607395B2Methods for improving neurological diseases and disordersCURASEN THERAPEUTICS INC·Filed 2020·Granted Mar 21, 2023·4 cites·26 claims
- 0390US10947196B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·2 cites·6 claims
- 0489US2025025462A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2024·Application pending·0 cites
- 0588US8524725B2Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseasesBROKA CHRIS ALLEN·Filed 2011·Granted Sep 3, 2013·9 cites·13 claims
- 0687US9284279B2Substituted pyrimidines for treatment of acute cough, chronic cough and urge to coughAFFERENT PHARMACEUTICALS INC·Filed 2014·Granted Mar 15, 2016·13 cites·20 claims
- 0785US11590107B2Methods for treating neurological disorders with α1A-AR partial agonistsCURASEN THERAPEUTICS INC·Filed 2020·Granted Feb 28, 2023·1 cites·28 claims
- 0883US11040944B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·1 cites·20 claims
- 0983US10822311B2Pyrimidines and variants thereof, and uses thereforAFFERENT PHARMACEUTICALS INC·Filed 2017·Granted Nov 3, 2020·3 cites·16 claims
- 1083US6355641B1Oxazolone derivatives and uses thereofSYNTEX LLC·Filed 2000·Granted Mar 12, 2002·14 cites·30 claims
- 1181US10662162B2Pyrimidines and variants thereof, and uses thereforAFFERENT PHARMACEUTICALS INC·Filed 2017·Granted May 26, 2020·2 cites·8 claims
- 1279US10676444B2Crystalline salts and polymorphs of a P2X3 antagonistAFFERENT PHARMACEUTICALS INC·Filed 2017·Granted Jun 9, 2020·1 cites·20 claims
- 1377US10206922B2Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute coughAFFERENT PHARMACEUTICALS INC·Filed 2017·Granted Feb 19, 2019·2 cites·20 claims
- 1476US9724346B2Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute coughAFFERENT PHARMACEUTICALS INC·Filed 2016·Granted Aug 8, 2017·2 cites·15 claims
- 1574US10195198B2Methods and compositions for treating diseases and conditionsAFFERENT PHARMACEUTICALS INC·Filed 2015·Granted Feb 5, 2019·2 cites·8 claims
- 1674US2021008071A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2020·Application pending·0 cites
- 1772US10543211B2Methods and compositions for treating diseases and conditionsAFFERENT PHARMACEUTICALS INC·Filed 2018·Granted Jan 28, 2020·1 cites·20 claims
- 1872US2023414588A1Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)CURASEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1972US2021371380A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2072US2025134835A1Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)CURASEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2170US12448352B2Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Granted Oct 21, 2025·0 cites·20 claims
- 2268US2024285620A1Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of coughAFFERENT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2366US11230533B2Crystalline salts and polymorphs of a P2X3 antagonistAFFERENT PHARMACEUTICALS INC·Filed 2020·Granted Jan 25, 2022·0 cites·19 claims
- 2466US2020108065A1Methods and compositions for treating diseases and conditionsAFFERENT PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2566US2018311240A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2018·Application pending·0 cites
- 2664US11591315B2Substituted pyrazole-pyrimidines, variants thereof, and uses thereforeAFFERENT PHARMACEUTICALS INC·Filed 2021·Granted Feb 28, 2023·0 cites·12 claims
- 2763US7531529B2Imidazole derivativesROCHE PALO ALTO LLC·Filed 2004·Granted May 12, 2009·2 cites·4 claims
- 2862US2013225570A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2013·Application pending·0 cites
- 2962US2025188060A1Alpha1a-adrenergic receptor agonists and methods of useCURASEN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3062US2022143015A1Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of coughAFFERENT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3161US2021121445A1METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH a1A-AR PARTIAL AGONISTSCURASEN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3260US11230532B2Pyrimidines and variants thereof, and uses thereforAFFERENT PHARMACEUTICALS INC·Filed 2020·Granted Jan 25, 2022·0 cites·12 claims
- 3360US2016271131A1Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseasesROCHE PALO ALTO LLC·Filed 2016·Application pending·0 cites
- 3459US2024270701A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3557US10988460B2Substituted pyrazole-pyrimidines, variants thereof, and uses thereforeAFFERENT PHARMACEUTICALS INC·Filed 2017·Granted Apr 27, 2021·0 cites·18 claims
- 3657US6733982B1Method for screening compounds for alpha1B adrenergic receptor antagonist and analgesic activitySYNTEX LLC·Filed 2000·Granted May 11, 2004·2 cites·14 claims
- 3757US6515198B2Use of purinergic receptor modulators and related reagentsSYNTEX LLC·Filed 2001·Granted Feb 4, 2003·8 cites·7 claims
- 3856US2024352002A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3956US2023312524A1Alpha1a-adrenergic receptor agonists and methods of useCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4054US2023157974A1Compositions and methods for improving neurological diseases and disordersCURASEN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4151US2022315534A1Beta adrenergic agonist and methods of using the sameCURASEN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4249US2023263749A1Compositions and methods for improving neurological diseases and disordersCURASEN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4346US11260056B2Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of coughAFFERENT PHARMACEUTICALS INC·Filed 2016·Granted Mar 1, 2022·0 cites·11 claims
- 4445US2021251923A1Methods for improving neurological diseases and disordersCURASEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4545US2021251559A1Methods for diagnosing, monitoring and treating neurological diseases and disordersCURASEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4638US2004132115A1Method for screening compounds for alpha1B adrenergic receptor antagonist and analgesic activityFiled 2003·Application pending·0 cites
- 4737US2003004157A1Use of NK-1 receptor antagonists against benign prostatic hyperplasiaFiled 2002·Application pending·0 cites
- 4834US2003135874A1Use of purinergic receptor modulators and related reagentsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anthony P. Ford files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →